These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 17550847)

  • 1. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
    Dbaibo GS; Kfoury Y; Darwiche N; Panjarian S; Kozhaya L; Nasr R; Abdallah M; Hermine O; El-Sabban M; de Thé H; Bazarbachi A
    Haematologica; 2007 Jun; 92(6):753-62. PubMed ID: 17550847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
    Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
    Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
    Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J
    Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
    Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
    Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide inhibits HCCLM3 cells invasion through de novo ceramide synthesis and sphingomyelinase-induced ceramide production.
    Zhang S; Zhou J; Zhang C; Wu H; Wang Y; Bian J; Guo J; Wu X
    Med Oncol; 2012 Sep; 29(3):2251-60. PubMed ID: 21773820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide and the growth of human T-cell leukemia virus type I infected T-cell lines.
    Ishitsuka K; Hanada S; Uozumi K; Utsunomiya A; Arima T
    Leuk Lymphoma; 2000 May; 37(5-6):649-55. PubMed ID: 11042529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.
    Freitas RA; Silva dos Santos GA; Gimenes Teixeira HL; Scheucher PS; Lucena-Araujo AR; Lima AS; Abreu e Lima RS; Garcia AB; Jordão AA; Falcão RP; Vannucchi H; Rego EM
    Leuk Res; 2009 Jul; 33(7):958-63. PubMed ID: 19013639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
    Ozpolat B; Akar U; Zorrilla-Calancha I; Vivas-Mejia P; Acevedo-Alvarez M; Lopez-Berestein G
    Apoptosis; 2008 Jul; 13(7):915-28. PubMed ID: 18491231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
    Takeshita A; Shinjo K; Naito K; Matsui H; Sahara N; Shigeno K; Horii T; Shirai N; Maekawa M; Ohnishi K; Naoe T; Ohno R
    Leukemia; 2005 Aug; 19(8):1306-11. PubMed ID: 15920495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
    Vivas-Mejía PE; Ozpolat B; Chen X; Lopez-Berestein G
    Int J Cancer; 2009 Jul; 125(2):264-75. PubMed ID: 19408305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation.
    Ishitsuka K; Ikeda R; Utsunomiya A; Uozumi K; Hanada S; Suzuki S; Takeuchi S; Takatsuka Y; Takeshita T; Ohno N; Arima T
    Leuk Lymphoma; 2002 May; 43(5):1107-14. PubMed ID: 12148893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
    Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.
    Ghaffari SH; Bashash D; Dizaji MZ; Ghavamzadeh A; Alimoghaddam K
    Tumour Biol; 2012 Feb; 33(1):157-72. PubMed ID: 22072212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct TP73-DAPK2-ATG5 pathway involvement in ATO-mediated cell death versus ATRA-mediated autophagy responses in APL.
    Humbert M; Federzoni EA; Tschan MP
    J Leukoc Biol; 2017 Dec; 102(6):1357-1370. PubMed ID: 28978663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin isoform expression in arsenic trioxide-treated acute promyelocytic leukemia cell line and patients: The odd expression pattern of survivin-2α.
    Zaki Dizaji M; Ghaffari SH; Hosseini E; Alizadeh N; Rostami S; Momeny M; Alimoghaddam K; Ghavamzadeh A
    Asia Pac J Clin Oncol; 2017 Apr; 13(2):e21-e30. PubMed ID: 27770503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
    Chen GQ; Zhou L; Styblo M; Walton F; Jing Y; Weinberg R; Chen Z; Waxman S
    Cancer Res; 2003 Apr; 63(8):1853-9. PubMed ID: 12702573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive antitumor effect of arsenic trioxide with exposure to ionizing radiation to human acute promyelocytic leukemia HL‑60 cells.
    Morino Y; Sugiyama H; Yamane K; Kikuchi M; Yamanaka T; Honda K; Monzen S
    Oncol Rep; 2024 Aug; 52(2):. PubMed ID: 38963046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4).
    Hassani S; Khaleghian A; Ahmadian S; Alizadeh S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Ann Hematol; 2018 Jan; 97(1):83-93. PubMed ID: 29159499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
    J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.